Xencor (XNCR) Earnings Date & Reports

Key Takeaways

• Third quarter 2026 revenue reached $116.5 million, up sharply from $21.0 million in the same period a year earlier.
• Net income came in at $39.4 million, or $0.50 per diluted share, versus a net loss of $6.0 million, or $(0.08) per share, in the prior-year quarter.
• Research and development (R&D) spending climbed to $84.3 million, while general and administrative (G&A) expenses fell to $9.4 million on a non-recurring legal expense recovery.
• The company reported $555.7 million in cash, cash equivalents, and marketable debt securities and expects to end 2026 with $480 million to $500 million.
• Results handily exceeded consensus estimates, with earnings per share (EPS) of $0.50 versus a projected $(0.31) loss and revenue well above the roughly $59.1 million forecast.
• For more detail on XNCR's Major News, Today's Price Move, Price Targets, and Forecast, explore the linked pages.
• Explore Trending AI Robots to discover automated trading strategies and market signals.

Earnings Context and Why It Matters

Xencor's third quarter 2026 report marks a meaningful shift for the clinical-stage biotech, which has historically posted quarterly losses as it funds a pipeline of engineered antibody candidates. A surge in collaboration revenue—driven by royalty payments from Alexion and Incyte and milestone revenue from Astellas—pushed the company into profitability, a rarity for early-stage developers. Investors are closely watching whether this revenue stream signals durable, non-dilutive funding that can reduce reliance on equity raises. The results also arrive against a backdrop of rising R&D investment, making the quarter a key test of Xencor's ability to convert partnered programs into steady income while advancing its own pipeline.

Reported Results

Xencor reported third quarter 2026 revenue of $116.5 million, compared with $21.0 million a year earlier. The increase was primarily attributed to royalty revenue from Alexion and Incyte plus milestone revenue from Astellas.

On the bottom line, the company posted net income attributable to Xencor of $39.4 million, or $0.50 on a fully diluted per share basis, reversing a net loss of $6.0 million, or $(0.08) per share, in the third quarter of 2025.

Research and development (R&D) expenses rose to $84.3 million from $54.4 million, reflecting higher internal and external development costs, partially offset by lower stock-based compensation. General and administrative (G&A) expenses declined to $9.4 million from $14.2 million, driven by a non-recurring recovery of legal expenses. Other income, net, fell to $16.4 million from $41.5 million on lower unrealized gains from an equity security.

Reported EPS of $0.50 significantly outperformed the consensus estimate of a $(0.31) loss, and revenue of $116.5 million surpassed the roughly $59.1 million analyst forecast. Cash, cash equivalents, and marketable debt securities totaled $555.7 million as of September 30, 2026.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Xencor, it offers a practical way to identify comparable opportunities across the biotechnology sector.

Market Reaction and Investor Sentiment

Xencor shares reacted positively to the results, rising modestly in after-hours trading following the release. The earnings beat—particularly the swing to a $0.50 per share profit against an expected loss—underscored investor enthusiasm for the company's growing royalty and milestone revenue base. Sentiment heading into the report had been constructive, with the stock up substantially over the trailing three- and twelve-month periods. The sharp revenue growth, driven by partnered programs rather than one-off items, appears to have reinforced confidence in Xencor's ability to generate non-dilutive cash flow. Key risk factors investors continue to weigh include the sustainability of royalty streams and rising R&D costs tied to the company's pipeline advancement.

Forward Outlook and Key Factors to Monitor

Looking ahead, Xencor reiterated its expectation to end 2026 with between $480 million and $500 million in cash, cash equivalents, and marketable debt securities, and to have sufficient resources to fund its R&D programs and operations into 2029.

Several factors merit attention. The Alexion settlement remains a meaningful cash source: Xencor received $52.5 million in August 2026 and is entitled to a final $52.5 million payment in the third quarter of 2027. Investors will also monitor the trajectory of royalty revenue from Alexion and Incyte, which drove much of the quarter's top-line strength.

Rising R&D expenses are likely to stay in focus as the company advances its pipeline, while any new milestone achievements from partners such as Astellas could add further revenue. The company's equity stake in Zenas—where obexelimab was licensed—represents an additional, potentially valuable asset. As always, clinical data readouts and regulatory progress will be central catalysts for a company whose long-term value depends heavily on development milestones.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations